Gregory J. Hughes PharmD, BCPS, CGP
Olga Hilas PharmD, MPH, BCPS, CGP, FASCP

In January 2014, the Daiichi Sankyo Company submitted a new drug application for the oral direct factor Xa inhibitor, edoxaban (Savaysa). Approval has been requested for the following indications: reduction in the risk of stroke and systemic embolic events in patients with nonvalvular AF; treatment of deep vein thrombosis or pulmonary embolism; and prevention of recurrent symptomatic VTE. Promising results from large clinical studies suggest that this new anticoagulant will likely be a competitor to other oral treatment options.

Kunj Gohil PharmD, RPh

Parkinson’s disease (PD) is a chronic, progressive ailment caused by neurodegeneration and a decreased concentration of dopamine in the brain, which ultimately leads to the brain’s inability to control body movements.1 The global prevalence in 2012 was approximately 2.18 million cases worldwide; this resulted in $3.56 billion in global market sales of therapies, including $1.15 billion in the U.S. market.

Stephen Barlas

The storm seeded by the pricing of Sovaldi has led payers, patients, and the federal government to seek cover from what some view as problematic pharmaceutical industry practices, including a few partly outside of the industry’s control.

Susan Worley

Lung cancer treatment has evolved in the past decade, leading to remarkable growth in the number and variety of therapeutic options. Clinicians and patients have witnessed a shift from a relatively small arsenal of mostly chemotherapeutic therapies to an expanding array of targeted treatments and treatment combinations. This change reflects, in part, a significant refinement in the molecular categorization of lung cancer and the increasingly successful exploitation of the molecular diversity of lung tumors.

Breaking News

Kappa opioid agonist reduces abuse potential
Once-daily pill works best in patients with abnormal kidney function
Treatment significantly reduces time to hemostasis versus gelatin sponge
Researchers assess effects of aspirin and statins
Up-and-coming technologies include mobile stroke ambulance and painless blood testing

Recent Headlines

Returning medical workers should not be quarantined, agency says
Author sees opportunity to improve stroke prevention
Experts point to increased risk of harm and uncertain benefits
Sphingosine 1-phosphate receptor modulator achieves clinical remission
AKB-6548 associated with serious adverse effects


From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash

A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.



Nashville, TN
November 3 to November 4
Brussels, Belgium
November 12 to November 14

P&T Past Issues

Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.